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Effects of naloxone and yohimbine in polycystic ovary syndrome: a rabbit model study
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Background/aim: To assess the therapeutic effects of naloxone and yohimbine on polycystic ovary syndrome (PCOS) in a rabbit model
in terms of body weight and endocrinological parameters (luteinizing hormone, insulin, and estradiol).
Materials and methods: A total of 50 adult, reproductively mature female rabbits (Oryctolagus cuniculus) were divided into five groups
(n = 10/group). In the control group PCOS was not induced (negative control group), whereas in the remaining four groups (n = 40)
PCOS was induced with a single i.m. injection of testosterone daily and were designated as follows: positive control, naloxone-treated
(NalT), yohimbine-treated (YohT), and naloxone+yohimbine-treated (NalYT) groups.
Results: A steadily ascending trend was noted in all of the studied parameters in the PCOS-induced group as compared to the negative
control group. All the parameters showed a descending trend in the NalT group as compared to the positive control. Regarding the YohT
and NalYT groups, all parameters showed a descending trend as compared to the positive control group except for estradiol.
Conclusion: Naloxone therapy either alone or combined with yohimbine improves a wide range of the clinical manifestations of PCOS.
Furthermore, we suggest this therapy as an alternative to the conventional therapy with insulin-lowering agents in vogue.
Key words: Polycystic ovary syndrome, naloxone, yohimbine

1. Introduction
Although polycystic ovary syndrome (PCOS) is
heterogeneous in nature and presents a wide variability in
its clinical manifestations, its primal indicators include
ovulatory dysfunction and hypergonadism (1). Its
correlation with hyperactivity of the sympathetic nervous
system, stress, and alteration in β-endorphins has been
extensively reported (2,3). Deregulation of the opioid system
influences the pancreatic β-cell function and ultimately leads
to obesity and PCOS (4). Furthermore, an intricate relation
between endogenous opioids, insulin, and GnRH output has
previously been elaborated (5,6).
Women of reproductive age belonging to all races and
nationalities have been found equally prone to PCOS (7). Its
presentation may, however, be variable among different races
and in people belonging to different geographical regions (8).
Wide variance has been reported regarding its prevalence
among populations and has been attributed to the effect of
ethnic origin, race, and environmental factors on phenotype
(9,10). A 20.7% prevalence of PCOS in the female population
of Pakistan has been reported (11). However, a more recent
work has reported the prevalence to be 81% and 44% in
women with and without hirsutism, respectively (12).
* Correspondence: umer.farooq@iub.edu.pk

Owing to its multietiological patterns, the treatment
regimens for PCOS are multifaceted and depend upon
its patternization (8). Insulin-lowering therapies have
been used as one of the regimens (13). However, the latest
trends include the use of drugs inhibiting the sympathetic
nervous and opioid system. The present study is the first of
its kind reported from Pakistan regarding the therapeutic
aspects of PCOS using naloxone and yohimbine in terms
of body weight and certain endocrinological parameters
in a rabbit model.
2. Materials and methods
2.1. Study animals and management
A total of 50 adult, reproductively mature female rabbits
(Oryctolagus cuniculus) ranging in age from 10 to 12
months were purchased from a local market in Lahore,
Pakistan. They were acclimatized to their housing and
feeding regimen for 2 weeks prior to the start of trial at
the animal house of Lahore College for Women University,
Lahore, Pakistan. An appropriate diet consisting of green
fodder given three times a day; vegetables, fruits, and dry
feed (grains such as wheat, corn and oat) twice a week; and
free access to water ad libitum was maintained.
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2.2. Experimental design
After acclimatization, all the rabbits were randomly
divided into five groups (n = 10/group). In the control
group PCOS was not induced and it was denoted as the
negative control group. The remaining animals (n = 40),
however, were given a single i.m. injection of testosterone
(Testosterone Depot, Schering, Berlin, Germany) daily for
4 weeks at the dosage rate of 4 mg/kg for the induction of
polycystic ovaries (14,15). After inducing PCOS, they were
assigned to four groups (n = 10/group) as described below.
The first group was given no treatment and was denoted
as the positive control group.
The second group (NalT) was administered 0.1 mg/
kg of naloxone i.m. (naloxone hydrochloride inj., USP 0.4
mg/mL, Hospira Inc., Maidenhead, UK) for the inhibition
of the opioid system (16).
The third group (YohT) was given 1 mg/kg of
yohimbine i.m. (yohimbine hydrochloride inj., Lloyd
Inc., Shenandoah, IA, USA) for the inhibition of the
sympathetic nervous system (16).
The fourth group (NalYT) was administered both
0.1 mg/kg naloxone and 1 mg/kg yohimbine i.m. for the
inhibition of both the opioid and sympathetic nervous
systems (16).
The treatments were carried out on a daily basis
for a total of 5 weeks during which weekly monitoring
was maintained for the assessment of body weight and
endocrinological parameters.
2.3. Sample collection and analysis
Blood samples (4 mL) were collected aseptically from
the marginal ear vein of each animal, on a weekly basis,
under a proper restraining protocol. They were transferred
into vacutainers containing thixotropic gel separator for
serum separation. Serum was harvested and analyzed for
luteinizing hormone (LH), insulin, and estradiol through
commercially available enzyme linked immunosorbent
assay (ELISA) kits as described in Table 1. Body weight
was measured prior to each sample/blood collection.

2.4. Statistical analysis
Statistical analysis was conducted with the Statistical
Package for the Social Science (SPSS for Windows version
12, SPSS Inc., Chicago, IL, USA). Results were expressed
as mean ± SE. The statistical difference between the
positive and negative control groups was assessed by
t-test whereas that between various treatments was tested
through repeated measures analysis of variance, followed
by Bonferroni post-hoc test.
3. Results
The comparative means (±SE) of body weight and certain
endocrinological parameters between the negative and
positive control (PCOS-induced) groups are presented
in Table 2. A steadily ascending trend was observed
in all of the studied parameters for the PCOS-induced
group across the study weeks. Statistical significance was,
however, achieved in varying weeks and at varying level.
Body weight was significantly higher in weeks 3, 4, and 5
(P < 0.05); LH in weeks 2 and 3 (P < 0.05), and 4 and 5 (P <
0.01); estradiol in weeks 1, 2, and 3 (P < 0.05), and 4 and 5
(P < 0.01); and insulin in weeks 1, 2, 3, 4, and 5 (P < 0.01).
The comparative means (±SE) of body weight and
certain endocrinological parameters between the PCOSinduced (positive control) group and the various treatment
groups are presented in Figure 1. All the parameters
showed a descending trend in the NalT group as compared
to the positive control group. Statistical significance was,
however, achieved in varying weeks and at varying level.
Body weight was significantly lower in weeks 4 and 5 (P
< 0.05); LH in weeks 3 and 4 (P < 0.05), and 5 (P < 0.01);
estradiol in weeks 2 and 3 (P < 0.05), and 4 and 5 (P <
0.01); and insulin in weeks 4 (P < 0.05) and 5 (P < 0.01).
Regarding the YohT group, all parameters showed
a descending trend as compared to the positive control
group except for estradiol. Body weight was significantly
lower in weeks 4 and 5 (P < 0.05); LH in weeks 1 (P <
0.05) and 2, 3, 4, and 5 (P < 0.01); and insulin in weeks 1,
2, 3, 4, and 5 (P < 0.01). Estradiol, in contrast, revealed an

Table 1. Detail of commercial kits used for assessment of various hormones of the study.

Attribute

Make and batch no.

Luteinizing hormone

Precision %

Sensitivity

Within assay

Between assay

LH ELISA Kit, FR E-2600, Labor Diagnostika Nord
GMBH & Co. KG. Germany

4.5, 2.7, 2.9

5.1, 8.1, 9.2

0.2 IU/L

Estradiol

Estradiol ELISA Kit, BC1111, Biocheck, Inc. Foster City
CA, USA.

24.1, 10.3, 4.1, 4.9

26.7,10.3,
6.4, 6.6

10 pg/mL

Insulin

Insulin ELISA Kit, YK060, HOLZEL Diagnostika,
Hansaring, Deutschland (Germany).

2.4, 3.0, 4.2

5.8, 5.0, 3.8

0.5 U/mL
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Table 2. Body weight and certain endocrinological parameters between negative and positive control (PCOS-induced) groups.
Values are presented as mean ± SE. * P < 0.05; **P < 0.01.
Weeks

Parameters
Body weight (kg)
Luteinizing hormone (IU/L)
Estradiol (pg/mL)
Insulin (U/mL)

Groups

Week 1

Week 2

Week 3

Week 4

Week 5

Negative control

1.05 ± 0.02

0.96 ± 0.04

0.98 ± 0.03

0.98 ± 0.03

0.99 ± 0.01

Positive control

1.05 ± 0.05

1.17 ± 0.04

1.25 ± 0.05*

1.29 ± 0.05*

1.29 ± 0.07*

Negative control

2.03 ± 0.02

2.10 ± 0.03

1.88 ± 0.09

1.98 ± 0.01

1.84 ± 0.03

Positive control

3.76 ± 0.24

4.31 ± 0.13*

4.68 ± 0.09*

5.25 ± 0.16**

5.24 ± 0.14**

Negative control

5.08 ± 0.04

5.08 ± 0.04

4.38 ± 0.19

4.33 ± 0.15

4.35 ± 0.12

Positive control

13.80 ± 0.18*

15.10 ± 0.10*

16.10 ± 0.14*

17.60 ± 0.17**

17.7 ± 0.17**

Negative control

1.42 ± 0.36

1.15 ± 0.35

0.92 ± 0.23

0.93 ± 0.22

0.97 ± 0.22

Positive control

8.00 ± 1.77**

8.59 ± 1.85**

9.36 ± 1.76**

10.21 ± 1.79**

10.22 ± 1.02**

ascending trend as compared to that in the positive control
group, being significantly higher in weeks 2 (P < 0.05), and
3, 4, and 5 (P < 0.01) (Figure 1).
For the NalYT group, the mean results in comparison
to the positive control group were the same as those for
the YohT group. A descending trend was noted for all

1.2
1
0.8
0.6
0.4
0.2

4. Discussion
A steadily ascending trend was seen for all of the studied
parameters (body weight, LH, insulin, and estradiol)

Luteininzing Hormone (IU/L)

1.4
Body Weight (kg)

YohT
NalYT

Positve Control
NalT

1.6

parameters except estradiol, which was found to be higher
in weeks 2 (P < 0.01) and 3, 4, and 5 (P < 0.05) (Figure 1).

(a)

5
4
3
2
1

(b)

0

0
Week 1

Week 2

Week 3

Week 4

Week 5

Week 1

Experiment (Weeks)

35

Insulin (U/mL)

Estradiol (pg/mL)

Week 4

Week 5

YohT
NalYT

10

20
15
10

8
6
4
2

(c)

0
Week 1

Week 3

Positve Control
NalT

12

25

0

Week 2

Experiment (Weeks)

YohT
NalYT

Positve Control
NalT

30

5

YohT
NalYT

Positve Control
NalT

6

Week 2

Week 3

Week 4

Experiment (Weeks)

Week 5

(d)
Week 1

Week 2

Week 3

Week 4

Week 5

Experiment (Weeks)

Figure 1. Body weight (a), luteinizing hormone (b), estradiol (c), and insulin (d) levels between the negative and positive (PCOSinduced) groups.

1267

SAJJAD et al. / Turk J Med Sci
for the PCOS-induced group across the study weeks.
It has been established that PCOS is characterized by
obesity and/or overweight as compared to non-PCOS
women (17), elevated LH (18), insulin (19), and estradiol
(20) hormones. In present study, PCOS was induced
in the animals by injecting testosterone (4 mg/kg) for
4 consecutive weeks. This leads to increased levels of
circulatory androgens (testosterone), which are then
converted into estrogens by aromatase activity (21).
However, in PCOS animals, increased amplitude and
frequency of LH pulse can be attributed to rapid GnRH
stimulation through the positive feedback mechanism
of the circulatory estrogens on adenohypophysis (18).
This increased LH further produces androstenedione
from stromal and thecal cells of the ovary and finally it is
again converted to estrone, exerting a tonic effect on LH
production. Regarding the elevated insulin concentration
in the positive control group, it can be attributed to shortterm testosterone treatment causing alterations in the
expression of lipolytic signaling proteins (22) of bodily
adipose tissue in relation to lipolytic activity and insulin
resistance (23) in the PCOS group. Furthermore, insulin
resistance and hyperinsulinemic conditions through
their individual or combined effect contributed towards
increased body weight in the PCOS group (24).
Naloxone is an opioid receptor antagonist and causes
blockage of hypothalamic opioid receptors and reduces the
opioid tone (5). It is used for the inhibition of the opioid
system, for overdose reversal, and as a therapeutic agent
(19). In the present study, body weight, LH, estrogen, and
insulin showed a descending trend in the NalT group
as compared to the positive control group. These results
are consistent with various studies on PCOS that have
elaborated that the opioid antagonist naltrexone has a
positive effect on normalization of body weight (20,25),
LH (19), estrogen (19), and insulin (26) in the PCOS
group. Naloxone can be suggested to impart its effect on
body weight by decreasing opioid peptide β endorphin
level (27,28) and regulating food intake through its effect
on the appetite center (25). However, the decline in LH
and estrogen level can be attributed to inhibition of
GnRH by naloxone in hyperinsulinemic PCOS women
(29). Similarly, the decrease in insulin level can be due
to its action on insulin secretion by reducing it up to
30% without causing change in the composition of β cell
secretion (20,30). Consequently, all these parameters were
changed in PCO-induced animals and were observed to be
normal after treatment with naloxone.
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Yohimbine is an antagonist of the sympathetic nervous
system and decreases sympathetic nerve activity and
increases plasma norepinephrine level without increasing
sympathetic nerve activity (5,31). Sympathetic and
hypothalamic–pituitary–adrenal axis (HPA) activity is
increased in PCOS subjects (32). Regarding the YohT group,
all parameters showed a descending trend as compared to
the positive control group except estradiol. A decline has
been reported for body weight of the PCOS group after
treatment with yohimbine earlier (33). Similarly, a decline
in LH concentration after yohimbine therapy in the PCOS
group and normalization of ovulatory cycles by increased
concentration of estrogen in PCOS rats as compared to the
control group has also been reported (31). These alterations
in endocrinological parameters and body weight can be
due to yohimbine-induced dysregulation in PCOS (34).
However, alterations in ovulatory cycles as an increased
concentration of estrogen in the PCOS group as compared
to the control group are contrary to previous reports.
For the NalYT group, the mean results in comparison
to the positive control group were the same as those for
the YohT group. A descending trend was noted for all
parameters except estradiol. It has been established that
the opioid and sympathetic nervous systems interact and
cause dysregulation in PCOS (34). Hyperinsulinemia,
hyperandrogenism, insulin resistance, cardiovascular
disorders, and obesity have been attributed to hyperactivity
of the sympathetic nervous system (18,35). Therefore,
for effective control of this increased activity of the
opioid and sympathetic nervous systems in the PCOS
group, naloxone and yohimbine were administered
simultaneously to experimental animals in the present
study. The descending trend in studied parameters (body
weight, LH, and insulin) except for estradiol in the PCOSinduced animals was consistent with recent work (31,36).
However, contrary to previous studies, the interaction
of the opioid and sympathetic nervous systems results
in increased concentration of estradiol in experimental
animals as compared to the positive control group. This
ascending trend in estrogen could be attributed to an
adjunct interaction of naloxone- and yohimbine-induced
dysregulation in PCOS.
In a nutshell, naloxone therapy either alone or
combined with yohimbine improves a wide range of
clinical manifestations of PCOS. We suggest this therapy
as an alternative to the conventional therapy of insulinlowering agents in vogue. Randomized controlled trials
need to be carried out in order to confirm these findings.
Furthermore, possible teratogenicity may also be examined.
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